Abstract
The vesicular acetylcholine transporter (VAChT) is a glycoprotein responsible for the accumulation of acetylcholine into pre-synaptic vesicules of cholinergic neurons. Cholinergic innervation has been shown to be decreased at the earlier stages of Alzheimer's disease (AD). Thus, the expression of VAChT has been correlated with the severity of the dementia and has been considered as a significant diagnostic target for AD. To this end numerous radioligands based on the vesamicol scaffold have been developed for imaging the VAChT using positron emission tomography (PET). Among the various radioligands only a small number have been evaluated in vivo in non-human primate and human. Despite promising in vitro, ex vivo and first in vivo studies, most of them are unsuitable for clinical use in humans due to poor selectivity over σ receptors, low extraction from the blood, slow brain kinetics or fast metabolism. To date (-)-[11C]OMV (1), (-)-[11C]MABV (2), (-)-[18F]-FEOBV (6), (-)-trans-2-hydroxy-3-(4-(4-[18F]fluorobenzoyl)piperidine) tetralin (8) and [18F]FBMV (12) are promising radioligands for the VAChT, though further validation is required to confirm their clinical usefulness.
Keywords: VAChT, Alzheimer’s disease, benzovesamicol, positron emission tomography, fluorine-18, carbon-11, PET.
Current Topics in Medicinal Chemistry
Title: PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Volume: 10 Issue: 15
Author(s): Nicolas Giboureau, Ian Mat Som, Aurelie Boucher-Arnold, Denis Guilloteau and Michael Kassiou
Affiliation:
Keywords: VAChT, Alzheimer’s disease, benzovesamicol, positron emission tomography, fluorine-18, carbon-11, PET.
Abstract: The vesicular acetylcholine transporter (VAChT) is a glycoprotein responsible for the accumulation of acetylcholine into pre-synaptic vesicules of cholinergic neurons. Cholinergic innervation has been shown to be decreased at the earlier stages of Alzheimer's disease (AD). Thus, the expression of VAChT has been correlated with the severity of the dementia and has been considered as a significant diagnostic target for AD. To this end numerous radioligands based on the vesamicol scaffold have been developed for imaging the VAChT using positron emission tomography (PET). Among the various radioligands only a small number have been evaluated in vivo in non-human primate and human. Despite promising in vitro, ex vivo and first in vivo studies, most of them are unsuitable for clinical use in humans due to poor selectivity over σ receptors, low extraction from the blood, slow brain kinetics or fast metabolism. To date (-)-[11C]OMV (1), (-)-[11C]MABV (2), (-)-[18F]-FEOBV (6), (-)-trans-2-hydroxy-3-(4-(4-[18F]fluorobenzoyl)piperidine) tetralin (8) and [18F]FBMV (12) are promising radioligands for the VAChT, though further validation is required to confirm their clinical usefulness.
Export Options
About this article
Cite this article as:
Giboureau Nicolas, Mat Som Ian, Boucher-Arnold Aurelie, Guilloteau Denis and Kassiou Michael, PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT), Current Topics in Medicinal Chemistry 2010; 10 (15) . https://dx.doi.org/10.2174/156802610793176846
DOI https://dx.doi.org/10.2174/156802610793176846 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Peptides for Therapy and Diagnosis of Alzheimer's Disease
Current Pharmaceutical Design Nature and Nurture: Genetic Influences and Gene-Environment Interactions in Depression
Current Psychiatry Reviews In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles
Current Alzheimer Research Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews Vaccination of Older Adults with Dementia Against Respiratory Infections
Infectious Disorders - Drug Targets Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry ADF/Cofilin-Actin Rods in Neurodegenerative Diseases
Current Alzheimer Research Pleiotropic Effect of Statins as Antioxidants on Cardiac Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry Patenting Penicillium Strains
Recent Patents on Biotechnology Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential
Current Alzheimer Research Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Current Neuropharmacology Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice
Current Alzheimer Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews